Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal
April 25, 2026
Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine…
The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia
March 26, 2026
Zoonotic malaria caused by infection with the monkey parasite Plasmodium knowlesi has emerged across Southeast Asia, particularly in areas previously close to…
Predicting risk of Plasmodium vivax microscopy-detected episodes using serological markers in patients with Plasmodium falciparum malaria: a multi-country diagnostic performance evaluation
March 17, 2026
Background: Plasmodium vivax presents a significant obstacle to malaria elimination due to its capacity to form dormant liver-stage hypnozoites that can…
Chronic Malaria Is Associated With Trauma-related Splenic Rupture Requiring Splenectomy
March 17, 2026
Splenic rupture is a recognized complication of acute Plasmodium falciparum and Plasmodium vivax malaria, but the risk of splenic rupture…
Extreme Genetic Diversity and Signatures of Balancing Selection in Plasmodium vivax Blood-Stage Antigens
March 17, 2026
Background: Knowledge of the genetic diversity of Plasmodium vivax antigen vaccine candidates can offer valuable insights into antigens targeted by host…
Assessment of antibody responses to Anopheles SG6-P1 and Aedes N-term 34 kDa salivary peptides: a randomised human-challenge trial of controlled exposures to vector bites
March 2, 2026
Background: Human antibodies against mosquito salivary proteins are proposed as proxy biomarkers of exposure to vector bites. This trial sought to…
Comparison of CD4 T cell response in Plasmodium falciparum and vivax malaria
February 27, 2026
Background: Plasmodium falciparum and P. vivax are parasites responsible for most malaria cases globally. In areas where these species co-exist, individuals…
A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria
February 26, 2026
Plasmodium vivax is the most widespread cause of malaria with a high burden of disease. Progress in reducing the global malaria…
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial
February 11, 2026
Background Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmodium vivax infections, but there are…
Strengthening the health systems at national level for malaria elimination in the Greater Mekong Subregion countries: a qualitative study
February 5, 2026
Background: Countries in the Greater Mekong Subregion (GMS) have committed to eliminating malaria by 2030. The success of a national malaria…